Managing skin side effects from cancer immunotherapy
Project 2: I CARE (Immunotherapy Cutaneous Adverse events REsearch)
This project looks at why some people on immune checkpoint inhibitors get inflammatory skin problems and how to spot and help those most likely to have worse outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | City College of New York NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11194445 on NIH RePORTER |
What this research studies
From a patient's point of view, the team collects blood and skin samples and combines medical, genetic, immune, and social-support information to understand who gets severe skin immune side effects from cancer immunotherapy. They focus on skin reactions because skin is easy to sample and often comes before other organ problems. The project links biology (like immune cell and HLA markers) with measures of stress and socioeconomic resources to find patterns that predict poor recovery. The investigators plan to use modern data methods to identify high-risk patients and design supportive approaches to reduce harm, especially for underserved groups.
Who could benefit from this research
Good fit: People receiving immune checkpoint inhibitors for cancer, especially those who develop or are at risk for immune-related skin problems, are the most likely candidates.
Not a fit: People not treated with immune checkpoint inhibitors or whose symptoms are unrelated to immune-related skin conditions would be unlikely to benefit directly.
Why it matters
Potential benefit: If successful, this work could help prevent or lessen skin side effects from immunotherapy and keep more patients on their cancer treatments.
How similar studies have performed: Prior research has identified risk factors for immune-related adverse events, but trials testing ways to reduce their impact—particularly in underserved populations—are still limited.
Where this research is happening
New York, United States
- City College of New York — New York, United States (Active)
Researchers
- Principal investigator: Vuong, Bao Q — City College of New York
- Study coordinator: Vuong, Bao Q
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.